{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:20:53Z","timestamp":1781418053399,"version":"3.54.1"},"reference-count":63,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/13543776.2024.2419826","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:37:31Z","timestamp":1729514251000},"page":"1215-1230","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["<i>Mycobacterium tuberculosis<\/i>\n            inhibitors: an updated patent review (2021\u2013present)"],"prefix":"10.1080","volume":"34","author":[{"given":"Salvucci","family":"Benedetta","sequence":"first","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1490-0428","authenticated-orcid":false,"given":"Francesco","family":"Vallini","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-1495","authenticated-orcid":false,"given":"Michela","family":"Guida","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-2512","authenticated-orcid":false,"given":"Chiara","family":"Tammaro","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Biava","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Poce","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drugs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Global Tuberculosis Report 2023. [cited 2024 Jul 9]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023"},{"key":"e_1_3_5_4_1","unstructured":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. [cited 2024 Jul 9].Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240048126"},{"issue":"24","key":"e_1_3_5_5_1","first-page":"00296","article-title":"Candidate anti-tuberculosis medicines and regimens under clinical evaluation","volume":"1198","author":"Hoelscher M","year":"2024","unstructured":"Hoelscher M, Barros-Aguirre D, Dara M, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024;S1198-743X(24):00296\u201300299.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528274"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1500286"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009939"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00426-5"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30770-2"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2012151"},{"key":"e_1_3_5_14_1","unstructured":"Clinical Portfolio. TB Alliance. [cited 2024 Jul 17]. Available from: https:\/\/www.tballiance.org\/portfolio"},{"key":"e_1_3_5_15_1","unstructured":"Cooper CB Huang H Zhang D et al. Substituted phenyloxazolidinones for antimicrobial therapy. US11964949B2. 2024."},{"key":"e_1_3_5_16_1","unstructured":"Upton AM Cooper CB Andries KJLM et al. Antibacterial compounds and uses thereof. US10981891B2. 2021."},{"key":"e_1_3_5_17_1","unstructured":"Pardal FAE CPRCP D Cordeiro SAV et al. Heterocyclic compounds for the treatment of tuberculosis. WO2023275744A1. 2023."},{"key":"e_1_3_5_18_1","unstructured":"Pardal FAE CPRCP D Cordeiro SAV et al. Antibacterial quinolines. US20230106913. 2023."},{"key":"e_1_3_5_19_1","unstructured":"\u6768\u5927\u6210 \u51af\u8ba1\u5468 \u8303\u8389 et al. \u6c1f\u55b9\u8bfa\u916e\u7c7b\u80fa\u57fa\u884d\u751f\u7269\u53ca\u5176\u7528\u9014. CN111087390B. 2022."},{"key":"e_1_3_5_20_1","unstructured":"Sun L Li Z. Pyrimidinone derivative preparation method thereof and use thereof in resisting Mycobacterium tuberculosis infection. US20230303561. 2023."},{"key":"e_1_3_5_21_1","unstructured":"Venugopala KN Attimarad M Nair AB et al. Antitubercular compounds. US11530217B1. 2022."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1919889"},{"key":"e_1_3_5_23_1","unstructured":"Venugopala KN Aldhubiab B Morsy MA et al. 7-isopropyl 1-ethyl\/methyl 3-(substituted benzoyl)-2-substituted indolizine-1 7-dicarboxylates as anti-tubercular agents. US11807640B1. 2023"},{"key":"e_1_3_5_24_1","unstructured":"Venugopala KN Deb PK Pillay M et al. 1-2(-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromides as anti-tubercular agents. US11919860B1. 2024."},{"key":"e_1_3_5_25_1","unstructured":"Venugopala KN Kandeel M Pillay M et al. 1-(2-(substituted phenyl)-2-oxoethyl)-3 5-dimethylpyridin-1-ium bromides as antitubercular agents. US11939294B1. 2024."},{"key":"e_1_3_5_26_1","unstructured":"Venugopala KN Deb PK Pillay M et al. 1-substituted benzoyl-4-bromopyrrolo[1 2-a]quinoline-3-carboxylate derivatives as antitubercular agents. US11919900B1. 2024."},{"key":"e_1_3_5_27_1","unstructured":"Venugopala KN Deb PK Pillay M et al. Substituted 7-methyl quinoline derivatives as antitubercular agents. US11926627B1. 2024"},{"key":"e_1_3_5_28_1","unstructured":"Venugopala KN Venugopala R Pillay M et al. Substituted 7 8-dihydropyrimido[4 5-d]pyrimidines as anti-tubercular agents. US11976076B1. 2024."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202002546"},{"key":"e_1_3_5_30_1","unstructured":"Gr\u0171ber G Bates RW Ng SP. Anti-tubercular compositions. WO2023191725A2. 2023."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02190-20"},{"key":"e_1_3_5_32_1","unstructured":"\u4e8e\u4e3d\u82b3 \u6c6a\u6f8d\u73af \u6c88\u5cbd\u7693 et al. \u4e00\u7c7b\u82ef\u5e76\u544b\u5583\u53ca\u82ef\u5e76\u544b\u5583\u9999\u8c46\u7d20\u884d\u751f\u7269\u53ca\u5176\u5236\u5907\u65b9\u6cd5\u548c\u5e94\u7528. CN109942523B. 2023."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr449"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.08.030"},{"key":"e_1_3_5_35_1","unstructured":"Tratrat C Haroun M. Indole-based chalcone compounds as antibacterial agents. US11731939B1. 2023."},{"key":"e_1_3_5_36_1","unstructured":"Tratrat C Haroun M. Benzofuro[3 2-c]chromen-6-one compounds as antibacterial agents. US11802130B1. 2023."},{"key":"e_1_3_5_37_1","unstructured":"Tratrat C Haroun M. Carbazole compounds as antibacterial agents. US11780809B1. 2023."},{"key":"e_1_3_5_38_1","unstructured":"Tratrat C Haroun M. Aminocarbazole compounds as antibacterial agents. US11807607B1. 2023."},{"key":"e_1_3_5_39_1","unstructured":"Pipeline | working Group for New TB Drugs. [cited 2024 Jul 22]. Available from: https:\/\/www.newtbdrugs.org\/pipeline\/clinical"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja211042r"},{"key":"e_1_3_5_41_1","unstructured":"Qiao C Dongguang F. Benzothiazinone derivative preparation method therefor and use thereof as anti-tuberculosis drug. WO2021203812A1. 2021."},{"key":"e_1_3_5_42_1","unstructured":"Qiao C Wu X. Benzothiazinone derivative based on alkynyl linking arm preparation method therefor and use thereof. WO2023065182A1. 2023."},{"key":"e_1_3_5_43_1","unstructured":"Kloss F Schieferdecker S Brakhage A et al. Antimicrobial compounds their use for the treatment of mammalian infections and a new metabolic mechanism. US11155542B2. 2021."},{"key":"e_1_3_5_44_1","unstructured":"Constantino LFV Pais JPA Delgado TAD et al. Benzoic acid derivatives methods and uses thereof. EP4345091A1. 2024."},{"key":"e_1_3_5_45_1","unstructured":"Sansano GJM Retamosa HMDG Foubelo GF et al. 2-(pyrrolidin-1-Yl)thiazole compounds and their use as antibiotic agents. WO2024028533A1. 2024."},{"key":"e_1_3_5_46_1","unstructured":"Crowley BM Nantermet P Olsen DB et al. Oxazolidinone compound and methods of use thereof as an antibacterial agent. WO2021184339A1. 2021."},{"key":"e_1_3_5_47_1","unstructured":"Choi I Kim YM Lee A et al. Oxazole derivative compound having antibacterial activity and medical use thereof. WO2023140709A1. 2023."},{"key":"e_1_3_5_48_1","unstructured":"Gajulapalli VPR. Novel 5-oxo-124-oxadiazole derivatives preparation method thereof and use thereof. KR102493756B1. 2023."},{"key":"e_1_3_5_49_1","unstructured":"Jiandong J Yuan L Yanxing H et al. Application of compound T0349 in preparation of anti-mycobacterium tuberculosis drugs. CN115590857A. 2023."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.01.022"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02829-7"},{"key":"e_1_3_5_52_1","unstructured":"Alley MRK Hernandez VS Plattner JJ et al. Tricyclic benzoxaborole compounds and uses thereof. US20210053999A1. 2021."},{"key":"e_1_3_5_53_1","unstructured":"Alemparte-Gallardo C Alley MRK Barros-Aguirre D et al. 4-substituted benzoxaborole compounds and uses thereof. US11214582B2. 2022."},{"key":"e_1_3_5_54_1","unstructured":"Bates R Encinas L Cleghorn L a T et al. Compounds. WO2023156648A1. 2023."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00088-12"},{"key":"e_1_3_5_56_1","unstructured":"Tan DS Standke LC Quadri LEN et al. Salicyl-adenosinemonosulfamate analogs and uses thereof. US2022162209A1. 2022."},{"key":"e_1_3_5_57_1","unstructured":"Bartolom\u00e9-Nebreda JM Mart\u00edn-Mart\u00edn ML Lamprecht DA et al. Imidazopyridine amides and related compounds for use in the treatment of bacterial infections. WO2023073090A1. 2023."},{"key":"e_1_3_5_58_1","unstructured":"Guillemont J\u00c9G Motte MMS Lamprecht DA et al. Antibacterial compounds. WO2022194905A1. 2022."},{"key":"e_1_3_5_59_1","unstructured":"Alemparte-Gallardo C Encinas L Esquivias PJ. Tetrazole compounds and their use in the treatment of tuberculosis. US11072591B2. 2021."},{"key":"e_1_3_5_60_1","unstructured":"Sun JJ Yang W Xu Z et al. Phenanthridinium derivatives as Ppm1a inhibitors and uses thereof. WO2023039662A1. 2023."},{"key":"e_1_3_5_61_1","unstructured":"Chen J Chen X Jiang C et al. Tetrahydrocarbazole derivative as well as preparation method therefor and use thereof. WO2023151359A1. 2023."},{"key":"e_1_3_5_62_1","unstructured":"Ghatpande N Shaikh M Jadhav J. Tricyclic spiro[chromane-2 4\u2019-piperidin]-4(3h)-one with 1 3 4-oxadiazole linkers compositions and process for preparation thereof. WO2023170699A1. 2023."},{"key":"e_1_3_5_63_1","unstructured":"Trotsko N Golus J Ginalska G et al. Pochodne kwasu (2 4-diokso-1 3-tiazolidyn-5-ylo\/ylideno)octowego z pirydyno-4-karbohydrazydowym podstawnikiem spos\u00f3b ich otrzymywania oraz zastosowanie medyczne. PL240816B1. 2022."},{"key":"e_1_3_5_64_1","unstructured":"Trotsko N Golus J GINALSKA G et al. Pochodne kwasu (2 4-diokso-1 3-tiazolidyn-5-ylo\/ylideno)octowego z tiosemikarbazydowym podstawnikiem spos\u00f3b ich otrzymywania oraz ich zastosowanie medyczne. PL240815B1. 2022."},{"key":"e_1_3_5_65_1","unstructured":"Oh D-C Hwang S Shin J et al. Pharmaceutical composition containing macrolide compound production method therefor and method using same. US2023094006A1. 2023."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2419826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:01:25Z","timestamp":1733227285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2419826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/13543776.2024.2419826"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2419826","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}